Bardet-Biedl Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Bardet-Biedl syndrome markets reached a value of US$ 248.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 403.8 Million by 2034, exhibiting a growth rate (CAGR) of 4.53% during 2024-2034.
The Bardet-Biedl syndrome market has been comprehensively analyzed in IMARC's new report titled "Bardet-Biedl Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bardet-Biedl syndrome is a rare and complex genetic disorder that affects several systems in the body. This disease primarily involves abnormalities in the function of cellular structures called cilia, which play essential roles in various biological processes. The most common feature of the ailment is retinal degeneration that can further lead to progressive vision loss and potential blindness. Numerous other indications include obesity, extra fingers or toes, intellectual disability, kidney dysfunction, behavioral problems, attention deficits, speech and language delays, etc. The severity and combination of these symptoms can vary significantly among patients. Additionally, individuals suffering from this disorder may experience health problems, such as high blood pressure, diabetes mellitus, and heart abnormalities. The diagnosis of Bardet-Biedl syndrome is typically based on a combination of clinical assessment, medical history review, and physical examination. The healthcare provider might also perform molecular genetic testing using blood or saliva samples to detect gene mutations associated with the condition. Furthermore, glucose tolerance tests and lipid profiles may be conducted to evaluate the metabolic status of the patient.
The increasing cases of genetic variations, which can disrupt the function and structure of cilia, impairing several cellular processes and signaling pathways in the body, are primarily driving the Bardet-Biedl syndrome market. In addition to this, the inflating utilization of physical and occupational therapies, since they help to improve gross and fine motor skills, muscle strength, and day-to-day living activities, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective medications like lipase inhibitors and metformin to aid in weight management by reducing fat absorption in the gut is further bolstering the market growth. Apart from this, the rising usage of non-pharmacological interventions, such as lifestyle modification, which includes consuming a balanced diet and practicing routine physical activity to preserve heart health and minimize the risk of disease complications, is acting as another significant growth-inducing factor. Additionally, the escalating popularity of gene therapy on account of its numerous advantages, like enhanced metabolic control, targeted treatment, long-term effects, etc., is expected to drive the Bardet-Biedl syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Bardet-Biedl syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Bardet-Biedl syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Bardet-Biedl syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Bardet-Biedl syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Bardet-Biedl syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Bardet-Biedl syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Bardet-Biedl syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Bardet-Biedl syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Bardet-Biedl syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of Bardet-Biedl syndrome across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of Bardet-Biedl syndrome by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of Bardet-Biedl syndrome by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with Bardet-Biedl syndrome across the seven major markets?
What is the size of the Bardet-Biedl syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Bardet-Biedl syndrome?
What will be the growth rate of patients across the seven major markets?
Bardet-Biedl Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Bardet-Biedl syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Bardet-Biedl syndrome market?
What are the key regulatory events related to the Bardet-Biedl syndrome market?
What is the structure of clinical trial landscape by status related to the Bardet-Biedl syndrome market?
What is the structure of clinical trial landscape by phase related to the Bardet-Biedl syndrome market?
What is the structure of clinical trial landscape by route of administration related to the Bardet-Biedl syndrome market?
The Bardet-Biedl syndrome market has been comprehensively analyzed in IMARC's new report titled "Bardet-Biedl Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bardet-Biedl syndrome is a rare and complex genetic disorder that affects several systems in the body. This disease primarily involves abnormalities in the function of cellular structures called cilia, which play essential roles in various biological processes. The most common feature of the ailment is retinal degeneration that can further lead to progressive vision loss and potential blindness. Numerous other indications include obesity, extra fingers or toes, intellectual disability, kidney dysfunction, behavioral problems, attention deficits, speech and language delays, etc. The severity and combination of these symptoms can vary significantly among patients. Additionally, individuals suffering from this disorder may experience health problems, such as high blood pressure, diabetes mellitus, and heart abnormalities. The diagnosis of Bardet-Biedl syndrome is typically based on a combination of clinical assessment, medical history review, and physical examination. The healthcare provider might also perform molecular genetic testing using blood or saliva samples to detect gene mutations associated with the condition. Furthermore, glucose tolerance tests and lipid profiles may be conducted to evaluate the metabolic status of the patient.
The increasing cases of genetic variations, which can disrupt the function and structure of cilia, impairing several cellular processes and signaling pathways in the body, are primarily driving the Bardet-Biedl syndrome market. In addition to this, the inflating utilization of physical and occupational therapies, since they help to improve gross and fine motor skills, muscle strength, and day-to-day living activities, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective medications like lipase inhibitors and metformin to aid in weight management by reducing fat absorption in the gut is further bolstering the market growth. Apart from this, the rising usage of non-pharmacological interventions, such as lifestyle modification, which includes consuming a balanced diet and practicing routine physical activity to preserve heart health and minimize the risk of disease complications, is acting as another significant growth-inducing factor. Additionally, the escalating popularity of gene therapy on account of its numerous advantages, like enhanced metabolic control, targeted treatment, long-term effects, etc., is expected to drive the Bardet-Biedl syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Bardet-Biedl syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Bardet-Biedl syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Bardet-Biedl syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Bardet-Biedl syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Bardet-Biedl syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Bardet-Biedl syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Bardet-Biedl syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Bardet-Biedl syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Bardet-Biedl syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of Bardet-Biedl syndrome across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of Bardet-Biedl syndrome by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of Bardet-Biedl syndrome by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with Bardet-Biedl syndrome across the seven major markets?
What is the size of the Bardet-Biedl syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Bardet-Biedl syndrome?
What will be the growth rate of patients across the seven major markets?
Bardet-Biedl Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Bardet-Biedl syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Bardet-Biedl syndrome market?
What are the key regulatory events related to the Bardet-Biedl syndrome market?
What is the structure of clinical trial landscape by status related to the Bardet-Biedl syndrome market?
What is the structure of clinical trial landscape by phase related to the Bardet-Biedl syndrome market?
What is the structure of clinical trial landscape by route of administration related to the Bardet-Biedl syndrome market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BARDET-BIEDL SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BARDET-BIEDL SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BARDET-BIEDL SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 BARDET-BIEDL SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BARDET-BIEDL SYNDROME - UNMET NEEDS
10 BARDET-BIEDL SYNDROME - KEY ENDPOINTS OF TREATMENT
11 BARDET-BIEDL SYNDROME - MARKETED PRODUCTS
11.1 List of Bardet-Biedl Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 BARDET-BIEDL SYNDROME - PIPELINE DRUGS
12.1 List of Bardet-Biedl Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Setmelanotide - Rhythm
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BARDET-BIEDL SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BARDET-BIEDL SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BARDET-BIEDL SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bardet-Biedl Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bardet-Biedl Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bardet-Biedl Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bardet-Biedl Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bardet-Biedl Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bardet-Biedl Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bardet-Biedl Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bardet-Biedl Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bardet-Biedl Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bardet-Biedl Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bardet-Biedl Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bardet-Biedl Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bardet-Biedl Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bardet-Biedl Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bardet-Biedl Syndrome - Access and Reimbursement Overview
16 BARDET-BIEDL SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BARDET-BIEDL SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BARDET-BIEDL SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BARDET-BIEDL SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BARDET-BIEDL SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BARDET-BIEDL SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 BARDET-BIEDL SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BARDET-BIEDL SYNDROME - UNMET NEEDS
10 BARDET-BIEDL SYNDROME - KEY ENDPOINTS OF TREATMENT
11 BARDET-BIEDL SYNDROME - MARKETED PRODUCTS
11.1 List of Bardet-Biedl Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 BARDET-BIEDL SYNDROME - PIPELINE DRUGS
12.1 List of Bardet-Biedl Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Setmelanotide - Rhythm
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BARDET-BIEDL SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BARDET-BIEDL SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BARDET-BIEDL SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bardet-Biedl Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bardet-Biedl Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bardet-Biedl Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bardet-Biedl Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bardet-Biedl Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bardet-Biedl Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bardet-Biedl Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bardet-Biedl Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bardet-Biedl Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bardet-Biedl Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bardet-Biedl Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bardet-Biedl Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bardet-Biedl Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bardet-Biedl Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bardet-Biedl Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bardet-Biedl Syndrome - Access and Reimbursement Overview
16 BARDET-BIEDL SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BARDET-BIEDL SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BARDET-BIEDL SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
